Lead Product(s) : Lonodelestat
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : CSHL
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Santhera will provide lonodelestat and intellectual support for the scientists at CSHL who will conduct the non-clinical research program.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 27, 2020
Lead Product(s) : Lonodelestat
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : CSHL
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : NI-0101
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Edesa Biotech
Deal Size : $372.0 million
Deal Type : Licensing Agreement
Details : The companies singed this exclusive worldwide license to develop and commercialize two Phase 2-ready biologic drug candidates for all therapeutic, prophylactic and diagnostic applications.
Product Name : NI-0101
Product Type : Antibody
Upfront Cash : Undisclosed
April 20, 2020
Lead Product(s) : NI-0101
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Edesa Biotech
Deal Size : $372.0 million
Deal Type : Licensing Agreement